Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 4/20 | 0.52 |
| ▸ | TK1 | P04183 | 2/20 | 0.49 |
| ▸ | AHCY | P23526 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lobucavir SCHEMBL598707 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL5990162 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL10460499 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL418430 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL9615453 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL9615451 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL15630215 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL51918 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL7699733 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY | |
| Lobucavir SCHEMBL7166488 | 1.00 | HPRT1 (0.53) | HPRT1ADORA3PNPTK1AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5469 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR BIOTECHNOLOGY INC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | Vir Biotechnology, Inc. | 2025-10-02 | — | — | US | claimed |
| US-20250213469-A1 | DOSAGE FORMS OF ACTIVE SUBSTANCES USED AGAINST VIRAL DISEASES IN DRY POWDER INHALER DEVICE FOR SYMPTOMS CAUSED BY COVID-19 AND OTHER VIRAL LUNG DISEASES | PULMOCURES ILAC EGITIM DANISMANLIK A.S. | 2025-07-03 | — | — | US | claimed |
| US-20250145680-A1 | NOVEL INTERFERON VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF | REMD BIOTHERAPEUTICS, INC. (US) | 2025-05-08 | — | — | US | claimed |
| US-20250136682-A1 | ANTI-SIGLEC-3 ANTIBODIES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | ACADEMIA SINICA (TW) | 2025-05-01 | — | — | US | claimed |
| EP-4526339-A2 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | VIR Biotechnology, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4526338-A2 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR Biotechnology, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| CN-119546629-A | Compositions and methods for treating Hepatitis Delta Virus (HDV) infection and related diseases | 维尔生物科技公司 | 2025-02-28 | — | — | CN | claimed |
| WO-1999018071-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HCMV INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-04-15 | — | — | WO | claimed |
| WO-1999018072-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF HCMV INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1999-04-15 | — | — | WO | claimed |
| US-5879700-A | TREATING HERPES VIRUS INFECTIONS | HOSTETLER KARL Y (US) | 1999-03-09 | — | — | US | claimed |
| WO-1998047487-A1 | A NOVEL BIOADHESIVE DRUG DELIVERY SYSTEM BASED ON LIQUID CRYSTALS | DUMEX-ALPHARMA A/S (DK) | 1998-10-29 | — | — | WO | claimed |
| EP-0871489-A1 | A PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION OF AN ACTIVE SUBSTANCE TO OR THROUGH A SKIN OR MUCOSAL SURFACE | GS DEVELOPMENT AB (SE) | 1998-10-21 | — | — | EP | claimed |
| WO-1998017282-A1 | METHODS OF USING SUCROSE OCTASULFATE TO TREAT OR PREVENT ENVELOPED VIRUS INFECTION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-04-30 | — | — | WO | claimed |
| CN-1179718-A | Novel pharmaceutical composition | ASTRA AB (SE) | 1998-04-22 | — | — | CN | claimed |
| EP-0809498-A1 | NOVEL PHARMACEUTICAL COMBINATION | Astra Aktiebolag (SE) | 1997-12-03 | — | — | EP | claimed |
| WO-1997013528-A1 | A PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION OF AN ACTIVE SUBSTANCE TO OR THROUGH A SKIN OR MUCOSAL SURFACE | GS DEVELOPMENT AB (SE) | 1997-04-17 | — | — | WO | claimed |
| WO-1996024355-A1 | NOVEL PHARMACEUTICAL COMBINATION | ASTRA AKTIEBOLAG (SE) | 1996-08-15 | — | — | WO | claimed |